Understanding Glycemic Control in the Post-discharge Period through Blinded Continuous Glucose Monitoring

Introduction and Objective: Little is known about glycemic control in the immediate post-hospital discharge period. Methods: In this observational study, patients wore blinded Dexcom G6 Pro CGM during their hospital stays and for up to 10 days post-discharge. Clinical data were extracted from the electronic medical record. Percent time in range (70-180 mg/dl, %TIR), above range (>180 mg/dl, %TAR), below range (<70 mg/dl, %TBR), and episodes of hypoglycemia from the inpatient and post-discharge periods were calculated. The difference between inpatient and post-discharge glycemic control was analyzed with paired t-tests. Predictors of post-discharge glycemic control were evaluated with logistic regression. Results: This cohort of 24 adults (mean age 65.7 ± 13.6 years, 37.5% female) had post-discharge mean %TIR 43.9 ± 33.2%, mean %TAR 55.9 ± 33.3%, and median %TBR 0% (0, 0.04). Glycemic control was similar pre- and post-discharge (post-discharge vs inpatient %TIR -3.7 ± 22.5%, p=0.4). CGM detected 16 episodes of hypoglycemia <70 mg/dl post-discharge. Of the clinical factors assessed, only measures of inpatient glycemic control were associated with achieving post-discharge glycemic control (Table). Conclusion: Inpatient glycemic control may impact post-discharge glycemic control, though the mediators are unclear. CGM may be useful in identifying hypoglycemia after discharge. Disclosure: R. Patel: None. M. O'Connor: None. A. Sabean: None. A. Ashley: None. H. Zheng: None. J. Yan: None. B. Steiner: None. N. Anandakugan: None. M.M. Calverley: None. R. Bartholomew: None. E. Greaux: None. L.E. Castellanos: None. M.E. Larkin: None. S.J. Russell: Employee; Beta Bionics, Inc. Stock/Shareholder; Beta Bionics, Inc. M.S. Putman: Consultant; Anagram Therapeutics. Research Support; Dexcom, Inc. Other Relationship; Vertex Pharmaceuticals Incorporated. K.L. Flint: None. Funding: National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119699-S1 and T32DK007028); Dexcom Investigator Initiated Studies grant